These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 3314475)
1. A controlled study of the nephrotoxicity of mezlocillin and amikacin in the neonate. Adelman RD; Wirth F; Rubio T Am J Dis Child; 1987 Nov; 141(11):1175-8. PubMed ID: 3314475 [TBL] [Abstract][Full Text] [Related]
2. A controlled study of the nephrotoxicity of mezlocillin and gentamicin plus ampicillin in the neonate. Adelman RD; Wirth F; Rubio T J Pediatr; 1987 Dec; 111(6 Pt 1):888-93. PubMed ID: 3316564 [TBL] [Abstract][Full Text] [Related]
3. A comparative analysis of aztreonam + clindamycin versus tobramycin + clindamycin or amikacin + mezlocillin in the treatment of gram-negative lower respiratory tract infections. Rivera-Vazquez CR; Ramirez-Ronda CH; Rodriguez JR; Saavedra S Chemotherapy; 1989; 35 Suppl 1():89-100. PubMed ID: 2659296 [TBL] [Abstract][Full Text] [Related]
4. Randomized trial using piperacillin versus ampicillin and amikacin for treatment of premature neonates with risk factors for sepsis. Hammerberg O; Kurnitzki C; Watts J; Rosenbloom D Eur J Clin Microbiol Infect Dis; 1989 Mar; 8(3):241-4. PubMed ID: 2496993 [TBL] [Abstract][Full Text] [Related]
5. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Lerner SA; Schmitt BA; Seligsohn R; Matz GJ Am J Med; 1986 Jun; 80(6B):98-104. PubMed ID: 3524221 [TBL] [Abstract][Full Text] [Related]
6. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis. Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719 [TBL] [Abstract][Full Text] [Related]
7. Aminoglycoside-related nephrotoxicity in the premature newborn. Rajchgot P; Prober CG; Soldin S; Perlman M; Good F; Harding E; Klein J; MacLeod S Clin Pharmacol Ther; 1984 Mar; 35(3):394-401. PubMed ID: 6365403 [TBL] [Abstract][Full Text] [Related]
8. C-reactive protein measurement: a reliable method of diagnosing and monitoring the infected newborn for the assessment of a mezlocillin therapeutic trial. Alt R; Irazuzta J; Erny P; Messer J; Monteil H; Minck R; Willard D J Antimicrob Chemother; 1983 May; 11 Suppl C():51-5. PubMed ID: 6619042 [TBL] [Abstract][Full Text] [Related]
9. The efficacy of mezlocillin-amikacin combination in febrile neutropenic children with oncologic disease. Zülfikar B; Devecioğlu O; Anak S; Ovali F; Gedikoğlu G J Chemother; 1991 Aug; 3(4):250-4. PubMed ID: 1779260 [TBL] [Abstract][Full Text] [Related]
15. Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. Williams PJ; Hull JH; Sarubbi FA; Rogers JF; Wargin WA J Clin Pharmacol; 1986 Feb; 26(2):79-86. PubMed ID: 3950060 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of aztreonam and ampicillin vs. amikacin and ampicillin for treatment of neonatal bacterial infections. Umaña MA; Odio CM; Castro E; Salas JL; McCracken GH Pediatr Infect Dis J; 1990 Mar; 9(3):175-80. PubMed ID: 2186351 [TBL] [Abstract][Full Text] [Related]
17. Prospective study of amikacin versus netilmicin in the treatment of severe infection in hospitalized patients. Noone M; Pomeroy L; Sage R; Noone P Am J Med; 1989 Jun; 86(6 Pt 2):809-13. PubMed ID: 2658582 [TBL] [Abstract][Full Text] [Related]